increasing duration of PbO 2 values < 15 mm Hg and instances of PbO 2 < 6 mm Hg. 29 No randomized trials have been conducted to evaluate PbO 2 -guided management in patients with TBI. Two studies compared outcomes in patients with TBI before and after the introduction of PbO 2 -guided management. Meixensberger et al. 19 observed that while PbO 2 -guided management of cerebral perfusion was associated with relative fewer episodes of cerebral hypoxia, there was no difference in 6-month neurological outcome. In a study of 53 patients, Stiefel et al. 28 reported that in patients who underwent PbO 2 -guided interventions the mortality rate was lower (25 and 44%, respectively) and neurological outcome was improved compared with patients without PbO 2 -guided interventions. Although the existing data suggest that episodes of cerebral hypoxia identified by PbO 2 monitoring are predictive of an adverse outcome in patients with severe TBI, it remains unclear whether PbO 2 -guided management of these patients is beneficial. The aim of the present study was to ascertain changes in clinical management associated with the use of PbO 2 monitoring and to estimate the association between the use of this monitoring modality and mortality rate, neurological outcome, and resource utilization in a large population of severe TBI patients.
Methods

Patient Population
The present study is based on the experience obtained in all patients with a diagnosis of severe TBI (admission GCS score ≤ 8) admitted to Harborview Medical Center (Seattle, Washington) between July 1, 2004 , and October 15, 2007 . Harborview Medical Center is a 413-bed municipal medical center affiliated with the University of Washington and is the only Level 1 trauma center in a 5-state area (Washington, Wyoming, Alaska, Montana, and Idaho). All data were available from the hospital database originating from computerized medical and billing records and from a prospectively collected registry of trauma-related admissions. 21 The study was approved by the University of Washington institutional review board, which waived the need for informed consent.
Monitoring
Patients were monitored using an ICP monitor (Camino, Integra NeuroSciences) alone or a PbO 2 monitor (Licox Brain Tissue Oxygenation Probe, Integra NeuroSciences) in addition to the ICP monitor. Indication for PbO 2 monitoring was based on the discretion of the attending neurosurgeon, without the use of specific guidelines with respect to the indication for placement. Both monitors were inserted through a triple-lumen bolt into the frontal region, using the same bur hole. The PbO 2 and/or ICP monitor was inserted within the first 48 hours of ICU admission. Preferred placement was into the healthy tissue on the side displaying maximal pathological features or swelling on CT scanning. Correct placement was confirmed by examining daily follow-up head CT scans. Hemodynamic and neurological variables were continuously monitored and recorded hourly using a bedside monitor.
Management
All patients with isolated TBI were admitted to the critical care unit and comanaged by neurological surgery and neurocritical care services, according to head-injury treatment guidelines issued by the Brain Trauma Foundation. 1 Trauma intensivists, with neurological surgery consultation, managed the cases of patients with multiple traumatic injuries.
Briefly, the threshold for treatment of brain tissue hypoxia was a PbO 2 < 20 mm Hg. A 100% FiO 2 challenge was performed to assess the reliability of PbO 2 values.
11 If the monitor was functioning properly, the FiO 2 challenge was followed by treatment corresponding to the severity of the patient's constellation of signs and symptoms. Patients with concomitant intracranial hypertension received intervention that was primarily directed at reducing ICP, according to CPP management guidelines.
Patients with hypoxic PbO 2 and without intracranial hypertension were treated with therapy directed to increase PbO 2 , according to 3 tiers of therapy escalation. Tier 1 management included adjustment of the head of bed to > 30°, temperature management to < 37.5°C, increasing CPP to > 60 mm Hg, 12 optimization of hemodynamic profile with volume replacement and cardiac output monitoring, and possible continuous jugular bulb O 2 saturation monitoring in the absence of a response to previous measures. Tier 2 management included increasing FiO 2 to 0.60 and transfusion of packed red blood cells to a target hemoglobin of ≥ 10 g/dl. 27 Tier 3 management included transient increase of FiO 2 to 1.0 to allow any benefit of increasing positive endexpiratory pressure 20 or aggressively reducing ICP with increased sedation, CSF drainage, or osmotic therapy.
Data Collection and Definitions
In addition to demographic data, the ISS, head AIS, GCS score, SAPS II, MABP, PaO 2 to FiO 2 ratio, and body temperature were recorded at ICU admission. The first noncontrast head CT scan was reviewed, and data were abstracted for pathology and features known to be associated with outcome. 14, 17, 18 The Marshall CT Classification Head Injury was used to assign degrees of brain injury severity based on the following characteristics of diffuse injury patterns: I, no intracranial disease; II, 0-5 mm midline shift, no mass lesion ≥ 25 ml; III, 0-5 mm midline shift, basal cisterns compressed or absent, no mass lesion ≥ 25 ml; and IV, > 5 mm midline shift, no mass lesion ≥ 25 ml. Mass lesions were identified as traumatic intracranial abnormalities with cumulative mass ≥ 25 ml and as to whether they were surgically evacuated. Midline shift > 5 mm and basilar cistern compression were also noted. Main intracranial diagnoses included epidural hematoma, subdural hematoma, traumatic SAH, intraparenchymal hemorrhage, features of diffuse axonal injury, and depressed skull fractures. Intraventricular blood was classified as SAH.
Both ICP and PbO 2 values were reported as the daily average value and the daily worst value recorded over the entire monitoring course. The type and frequency of therapeutic interventions, as described in the therapeutic injury level score, were also recorded. 15 Patients with > 2 consecutive days of serum sodium above 145 mEq/L were considered to have received hypertonic saline solution therapy. Hyperventilation was defined as PaCO 2 values ≤ 35 mm Hg for > 30 minutes. Mortality during hospitalization was evaluated. Scores of the FIM, on a scale from 1 to 4, were assessed at hospital discharge and included independence with feeding, locomotion, and expression. Scores for each category were added for a total maximum score of 12: 1, total dependence; 2, partial dependence; 3, independent with assistance; and 4, complete independence. Neurological outcome was assessed only in survivors. The LOS and duration of mechanical ventilation were also recorded.
Cost was analyzed from the institutional perspective. Hospital charges for each patient were obtained from hospital administrative records. Charges were converted to cost by applying the institution specific cost-to-charge ratio (0.668). Dollar values for cost have been adjusted for inflation and are reported in 2007 US dollars.
Statistical Analysis
Continuous variables are presented as mean ± SD. Means were compared using 2-sample t-tests with unequal variances between patients in the PbO 2 /ICP monitoring group and patients in the ICP-only monitoring group. Categorical variables are presented as frequency distribution. Comparisons between groups were made using chi-square test. All p values are 2 sided.
Regression analysis with robust variance estimates was used to investigate mean differences of the outcome measures. Unadjusted models that included only the main predictor of interest (that is, the type of neuromonitoring) were fitted to estimate mean differences in both monitoring groups. The estimates were then adjusted for a priori selected potential confounding factors, including age, admission GCS score, head AIS score, and Marshall CT classification. The adjusted models included type of neuromonitoring, significant predictors of death, and the confounders. The ISS and head AIS scores were included separately in the model to estimate the respective contribution of each component. Because the scores were highly collinear, we only included the head AIS score in the model to fully account for brain injury severity.
Multivariable linear regression was also used to model LOS and hospital charges after appropriate transformation. Because LOS and charges were skewed, they were log transformed before fitting the regression model.
To allow for sufficient time for the treatment encouraged by monitoring modality to have an effect, sensitivity analysis was used to explore associations between monitoring modality and hospital mortality rate, restricting the analysis to patients who survived beyond 48 hours after ICU admission.
A commercially available statistical program was used for all analyses (STATA for Macintosh, version 10.0; StataCorp).
Results
Patient Demographics
During the study period, 629 patients were admitted to Harborview Medical Center with a diagnosis of severe traumatic brain injury. Of these, 506 patients underwent insertion of an ICP monitor, and 123 patients underwent placement of both ICP and PbO 2 monitors. Demographic characteristics of the study population are shown in Table  1 . No important differences were noted with respect to sex, race/ethnicity, body mass index, SAPS II, MABP, PaO 2 / FiO 2 ratio, or body temperature at ICU admission. On average, patients in the ICP/PbO 2 group were younger and had more severe brain injuries than patients in the ICP-only group. The median admission GCS, mean ISS, and mean head AIS scores were worse in patients in whom a PbO 2 monitor was placed.
Patient Management
Neuromonitoring data and therapeutic interventions received during the ICU stay stratified by study group are shown in Table 2 . Patients in the PbO 2 /ICP-monitored group had the same average daily ICP values, but a greater number of episodes of intracranial hypertension, than patients in the ICP-only group. Patients who underwent PbO 2 /ICP monitoring received more aggressive management in many components of the therapeutic intensity level score, including administration of hypertonic saline, mannitol, use of vasopressors, and use of sedatives. There was no significant difference between the groups in the numbers of patients undergoing hyperventilation or surgical decompression. During the ICU stay, PbO 2 -monitored patients had a significantly lower worst PaO 2 /FiO 2 ratio compared with patients in the ICP-only group.
Mortality Rate
The cumulative hospital mortality rate was 29% in patients in the ICP/PbO 2 group and 23% in ICP-only group (Table 3 ). The crude difference in mortality rate was 6.7% (95% CI −2.1 to 15.6%). After adjustment for head AIS score, ICU admission GCS score, Marshall classification, and age, the excess mortality rate in the PbO 2 group persisted but to a smaller degree (4.4% [95% CI −3.9 to 12.7%]; Table 4 ).
Neurological Outcome
Relatively fewer patients in the ICP/PbO 2 -monitored group were discharged with a FIM score indicating some level of independence (FIM score ≥ 7) compared with the ICP-only group. The mean FIM score at discharge was 7.6 ± 3.0 in ICP/PbO 2 -monitored patients and 8.6 ± 2.8 in the ICP group (p < 0.01, Table 3 ). After adjustment, there was a −0.75 point difference (95% CI −1.41 to −0.09) in the mean FIM score in patients with PbO 2 monitoring compared with ICP-only monitoring.
Resource Utilization
Monitoring of PbO 2 was associated with increases in resource utilization compared with ICP monitoring alone ( Table 3 ). The unadjusted difference in the mean duration of mechanical ventilation was 3.5 days (95% CI 1.81-5.16). The adjusted mean difference in the duration of mechanical ventilation was a 2.96 days (95% CI 1.27-4.65).
The crude and adjusted ratios of median LOS and median hospital cost are shown in Table 4 . Following adjustment, there was a 27% relative increase in the median LOS and a 29% relative increase in the median hospital cost in the ICP/PbO 2 -monitored group compared with the ICP-only group ( Table 4 ).
Analyses that excluded patients who did not survive beyond the first 48 hours after trauma yielded results similar to those presented above.
Discussion
We observed no reduction in the hospital mortality rate in patients with severe TBI who were managed with ICP and PbO 2 monitoring compared with those who were managed with ICP monitoring only. In patients who survived, the likelihood of a good neurological outcome was smaller in the PbO 2 group compared with ICP-only group. The use of PbO 2 monitoring was associated with an increase in the number of therapeutic interventions, a longer course of mechanical ventilation, and an increased LOS, and thus with increased hospital costs.
The observational nature of our study design allows for the possibility that the patients with and without PbO 2 monitoring had an inherently different prognosis. Indeed, the patients who underwent PbO 2 monitoring were younger and had severer brain injuries as measured by the admission GCS score and the head AIS score. However, the decision to insert a PbO 2 monitor was made at the discretion of the admitting neurosurgeon, with variability in practice among physicians. While we attempted to adjust for these imbalances in baseline characteristics predictive of prognosis in our analyses, it is possible that residual confounding is present, and our results should be interpreted with this in mind. * Mean values are presented ± SD. Abbreviations: BMI = body mass index; IQR = interquartile range. † The Marshall CT classification was used to assign degrees of injury severity based on the following characteristics of diffuse injury patterns. See text for definition of classes. Mass lesions were identified as traumatic intracranial abnormalities with cumulative mass ≥ 25 ml and as whether they were surgically evacuated. In contrast to our results, Stiefel and colleagues 28 found a reduced risk of hospital death in patients with severe TBI after the initiation of PbO 2 -guided management. However, the patients who did and did not receive PbO 2 monitoring in that study were not comparable in a number of respects. Furthermore, the risk of in-hospital death after the introduction of PbO 2 monitoring (25%) was quite similar to that seen in our study of patients with TBI (irrespective of monitoring status) and in US trauma centers in general; 5 only the mortality rate (44%) in their earlier patient group differed.
We found a significant reduction in the odds of a better neurological outcome in patients who received PbO 2 -directed management. Although it has been previously reported that poor neurological outcome was associated with hypoxic PbO 2 values, 29, 30 few studies have investigated whether interventions directed at improving PbO 2 lead to better neurological outcome. In a small study, Meixensberger et al. 19 reported no significant difference in the proportion of patients with good neurological outcome (Glasgow Outcome Scale scores of 4-5) following a PbO 2 -guided treatment protocol to improve cerebral perfusion compared with patients in whom PbO 2 monitoring was not used to guide therapy. The outcomes were not adjusted for potential confounders, and it is unknown if the results would have been different after accounting for patient characteristics. In the present study, we attempted to control for confounding variables, and we used an assessment of FIMs at hospital discharge to quantify neurological outcome. It is difficult to make a direct comparison because neurological outcome was not reported in detail in previous studies. We found that patients were more likely to have a lower level of functional independence at hospital discharge if they had undergone ICP/PbO 2 monitoring rather than ICP monitoring only.
It is possible that the means of monitoring PbO 2 in the period during which our study took place, or of acting on the results, may have been less than ideal. Technical issues in human clinical use, improper positioning in a given injured brain, a very small monitored tissue volume, and device-related damage to the monitored tissue are all established complications associated with insertion of a PbO 2 monitor. 10 The treatment threshold could also be incorrect. In addition, recent work suggests that PbO 2 is more reflective of O 2 diffusion than O 2 delivery, and that PbO 2 may not be an effective "ischemia monitor." 25 Nonetheless, it could also be true that the therapeutic approach to desaturations may be ineffective or even have unfavorable risk-benefit ratios with respect to overall outcomes. Many more of the patients in the PbO 2 group received therapeutic interventions to manage hypoxic PbO 2 values, each with possible adverse systemic consequences. Aggressive treatment to improve CPP is associated with increased systemic complications, 24 and many of the same treatments are indicated for the management of hypoxic PbO 2 values. For example, the use of vasopressors to raise CPP is a risk factor for pulmonary complications, 7 and pulmonary complications such as acute lung injury have been associated with worse neurological outcome following TBI. 4 A greater proportion of patients with PbO 2 -guided management received vasopressors than the ICP-only group. The use of sedatives also was more frequent in the PbO 2 group. It is well documented that the use of heavy sedation causes increased duration of mechanical ventilation and LOS. 8, 13 
Conclusions
The data presented in this study suggest that there are reasons to question the efficacy of PbO 2 -guided management of patients with severe TBI. However, because of the potential for residual confounding in our observa- tional study, we recommend that a randomized trial be conducted to better address the question.
